A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ustekinumab approximately 6 mg/kg (IV)
DRUG: Placebo (SC)
DRUG: Placebo (IV)
DRUG: Ustekinumab 90 mg (SC) Group 1
DRUG: Ustekinumab 90 mg (SC) Group 2

Sponsor

Janssen-Cilag Ltd.